Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook
Demonstrated tangible market progress and shipped 17 instruments through year end 2021 REDWOOD CITY, Calif.,…
News
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4…
Berkeley Lights to Participate in Cowen 42nd Annual Health Care Conference
EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader…
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing…
Angion Announces Participation in Upcoming Investment Conferences
UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company…
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Generated $15.1 million in full year 2021 EMPAVELI® (pegcetacoplan) net product revenues; demonstrated strong initial…
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline…
Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
Phase I trial of BMF-219, an irreversible covalent menin inhibitor, is currently underway Plan to…
Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
FOSTER CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the…
Kinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care Conference
SAN FRANCISCO and SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq:…
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage…
BrainChip Appoints Antonio J. Viana as Chairman of the Board
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first…
Software AG Acquires StreamSets to Further Accelerate Rapid Growth in Hybrid Integration
StreamSets is a fast-growing, enterprise-grade provider of data integration for modern analytics with a four-year…
Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates
On Track for TRIDENT-1 ROS1+ NSCLC Topline Data Disclosure and Pre-NDA Meeting Anticipated 2Q 2022…
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and…
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI),…
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose…
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer…
Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome…
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
CSU Phase 1b multi-dose data expected in July CDX-0159 subcutaneous formulation study results fully support…